J&J (JNJ) to Recall Single Lot Of Johnson's Baby Powder in U.S. After Test Indicates Presence of Sub-trace Levels of Chrysotile Asbestos

Go back to J&J (JNJ) to Recall Single Lot Of Johnson's Baby Powder in U.S. After Test Indicates Presence of Sub-trace Levels of Chrysotile Asbestos

Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH

October 21, 2019 9:04 AM EDT

Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson (NYSE: JNJ), today announces new data evaluating initial combination therapy with OPSUMIT® (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial hypertension (PAH, WHO Group 1) taking this combination showed hemodynamic improvement, as well as improvements in functional parameters and risk profiles. The combination was also well tolerated in these patients. The study data is being shared today at the CHEST Annual Meeting 2019, held October 19-23 in New Orleans, Louisiana.

The OPTIMA (cOmbination theraPy of maciTentan and tadalafIl in patients with... More

Johnson & Johnson (JNJ) Trades at Low, Down 5%

October 18, 2019 12:20 PM EDT

Johnson & Johnson (NYSE: JNJ) Trades at Low, Down 5%

... More

J&J (JNJ) Extends Decline, Now Down 3.4% After Baby Powder Recall Tied to Traces of Asbestos

October 18, 2019 9:09 AM EDT

J&J (NYSE: JNJ) Extends Decline, Now Down 3.4% After Baby Powder Recall Tied to Traces of Asbestos

... More